来源：滚动播报 复星国际旗下保险公司Fidelidade的IPO估值据悉或超30亿欧元。 ...

Group 1 - Spot gold reached $5050 per ounce, with a daily increase of 0.54% [1] - Spot silver saw a daily increase of 1%, reaching $81.54 per ounce [1] - The gains for both gold and silver narrowed later in the day [1] Group 2 - MSCI announced its quarterly index adjustments effective after the market close on February 27, 2026 [1] - Notable additions to the MSCI China Index include 37 stocks such as Liou Co., Silver Holdings, Anji Technology, and Pony.ai [1] - The index will remove 16 stocks, including Fosun International, Great Wall Motors, and Vanke Enterprises [1]

医药赛道方面，2025年多项关键性的创新药BD为未来复星创新药的可持续性增长，打下了坚实的基 础。其中，复星医药控股子公司药友制药与辉瑞签订全球独家许可协议，授予辉瑞口服小分子GLP-1药 物YP05002全球范围内独家开发、生产及商业化权利，协议包含首付款、里程碑付款及销售分层特许权 使用费，潜在总金额超20亿美元；复星医药控股子公司复星医药产业与生物技术公司Clavis Bio达成战 略合作，双方将基于由Clavis Bio提名的前沿靶点共同开发创新疗法，根据协议，复星医药将可获得至 多72.5亿美元付款。 2026年开年以来，复星在旅文、医药、保险等核心赛道表现亮眼。公开信息显示，复星旗下ClubMed国 内5家精致"一价全包"度假村入境营业额较去年同期实现翻三倍增长，旗下生物医药研发平台复宏汉霖 宣布与卫材株式会社就抗PD-1单抗汉斯状在日本达成独家商业化及共同独家开发与生产许可协议，潜 在总金额超3亿美元。 新春旅游需求的承接及创新药的持续商业化落地等，延续了复星2025年核心赛道稳中有升的发展态势。 纵观复星过去一年的发展和今年的开年势头，"瘦身健体"的战略推进依旧坚定：退出一些非核心项目的 同时 ...

Core Insights - Fosun has reported significant growth in its core sectors, including tourism, pharmaceuticals, and insurance, with notable achievements in early 2026 [1][2][3] Tourism Sector Performance - Fosun's Club Med resorts in China saw a threefold increase in inbound revenue compared to the same period last year, with a 33% revenue growth during the New Year period [1][2] - The company launched three major product lines in 2025, resulting in 14 project signings, including five super resorts and eight super tourism zones [2] - The average occupancy rate for three ice and snow resorts exceeded 97%, while two sunshine resorts doubled their revenue [2] Pharmaceutical Sector Developments - Fosun Pharma's subsidiary signed a global exclusive licensing agreement with Pfizer for a GLP-1 drug, with potential total payments exceeding $2 billion [3] - The company is also collaborating with Clavis Bio for innovative therapies, with potential payments up to $7.25 billion [3] - Fosun's innovative drugs are expected to achieve significant market breakthroughs in 2026, with several products anticipated to receive regulatory approvals [3] Insurance Sector Growth - Fosun's insurance companies reported substantial growth, with Fosun United Health Insurance's revenue reaching 7.84 billion yuan, a 50% increase year-on-year [3][4] - Fosun Baodexin Life Insurance achieved a 36.2% revenue growth, totaling 12.6 billion yuan, with a net profit increase of over 450% [3][4] Financial Health and Strategy - Fosun has maintained a strong financial position, with a debt-to-capital ratio of 53% and a decrease in debt costs [5][6] - The company successfully executed significant equity sales, raising substantial funds to support its core business focus [6] - Fosun plans to reduce interest-bearing debt by approximately 10 billion yuan annually over the next two to three years, aiming for an "investment-grade" rating [6] Future Prospects - Fosun is preparing for potential IPOs of two subsidiaries, which could enhance strategic synergies and investment returns [7] - The company is well-positioned to capitalize on opportunities in the aging population and the growing demand for health and wellness, as well as tourism in emerging markets [7][8]

Core Insights - The meeting between Jiangsu Province Governor Liu Xiaotao and Fosun International Chairman Guo Guangchang highlights the ongoing collaboration and investment opportunities in Jiangsu, focusing on sectors like biomedicine, healthcare, cultural tourism, consumption, and finance [1] Group 1: Investment and Economic Development - Fosun has invested over 100 billion yuan in Jiangsu, establishing a strong presence across multiple industries [2] - The company aims to deepen its business cooperation in Jiangsu, leveraging its technological and talent advantages to meet local development needs [1][2] Group 2: Biomedicine Sector - Fosun Pharma has developed a collaborative industrial ecosystem in Jiangsu, with multiple innovative drugs and biosimilars launched in the past five years [2] - The company plans to maintain its R&D investment during the 14th Five-Year Plan, focusing on areas such as metabolism, hematology, oncology, respiratory, autoimmune, and ophthalmology [2] Group 3: Cultural Tourism and Consumer Sector - The Taicang Alps International Resort, developed by Fosun Tourism, has become a benchmark for the "ice and snow economy" in the Yangtze River Delta, attracting over 2 million visitors since its opening in November 2023 [3] - The Club Med resort in Nanjing has also gained popularity since its opening in October 2023, while the Suzhou Songhelou restaurant is expanding internationally with plans to open its first overseas location in London by April 2025 [3] Group 4: Collaboration in Emerging Technologies - Fosun is engaging in extensive collaborations with various regions in Jiangsu through investment funds, focusing on cutting-edge fields such as embodied intelligence, semiconductors, and new materials [3]

Group 1 - The meeting between Jiangsu Province Governor Liu Xiaotao and Fosun International Chairman Guo Guangchang highlights the importance of collaboration in various sectors such as biomedicine, healthcare, culture, tourism, consumption, and finance [1] - Governor Liu emphasized the ongoing efforts to integrate technological and industrial innovation in Jiangsu, aiming to accelerate the development of new productive forces [1] - Fosun International is committed to leveraging its strengths to meet Jiangsu's development needs and enhance cooperation across its business segments, contributing to the province's high-quality development [1] Group 2 - The meeting was attended by Nanjing Mayor Li Zhongjun and Provincial Government Secretary Zhao Jianjun, indicating a high-level engagement between government and business [2]

Market Overview - AMD's overnight drop of 17% triggered a significant decline in chip stocks, leading to a 1.95% drop in the Chinese concept index, which negatively impacted the Hong Kong stock market [1] - The Hang Seng Index fell by 340.88 points, or 1.27%, to 26,506.44 points, while the Hang Seng Tech Index decreased by 62.30 points, or 1.16%, to 5,304.14 points [1] - Major tech stocks like Tencent and Alibaba saw declines of nearly 3% and 2.5%, respectively, with Tencent's market value dropping below 500 billion [1] Company Performance - Xinda Biopharmaceuticals (01801.HK) projected total product revenue of approximately RMB 11.9 billion for 2025, reflecting a year-on-year growth of about 45% [2] - Lee & Man Paper Manufacturing (02314.HK) expects profits for 2025 to be between HKD 1.88 billion and HKD 2.00 billion, indicating a year-on-year increase of 38% to 47% [2] - ZTO Express (02057.HK) anticipates total revenue of RMB 48.5 billion to RMB 50 billion for 2025, representing a year-on-year growth of approximately 9.5% to 12.9% [2] - China Resources Cement (01313.HK) forecasts a year-on-year profit increase of about 115% to 135% for 2025, driven by reduced costs and impairment losses [2] Corporate Actions - Goldin Properties (00535.HK) reported a January contract sales total of approximately RMB 239 million, a year-on-year decrease of 61.82% [3] - Fosun International (00656.HK) plans to subscribe for additional registered capital of RMB 105 million in Shangmeng Technology, acquiring a 51.0879% stake post-increase [3] - Shanghai Pharmaceuticals (02607.HK) intends to publicly transfer its 30% stake in Bristol-Myers Squibb, with a minimum listing price of approximately RMB 1.023 billion [3] - China Coalbed Methane (08270.HK) completed the sale of 100% equity in Shanxi Qingshui Shuntai Energy Development [4] Investment Trends - The active repurchase of shares continues, with Kingsoft (03888.HK) repurchasing 1.0886 million shares for approximately HKD 29.99 million [9] - Xiaomi Group (01810.HK) repurchased 4.3 million shares for a total of HKD 146 million [10] - Kingdee International (00268.HK) repurchased 1 million shares for approximately HKD 11.1 million [11] Market Outlook - Guoyuan International's report suggests that the Hong Kong stock market may experience short-term volatility due to external factors, but maintains a positive long-term outlook [12] - CITIC Securities highlights the potential for new investment opportunities in emerging markets, despite risks from rising oil prices and long-term bond yields [12] - Galaxy Securities recommends focusing on technology, energy, precious metals, and consumer sectors for potential rebounds [13]

Summary of the Conference Call for Fosun International Industry and Company Overview - **Company**: Fosun International - **Industry**: Diversified Holdings including healthcare, consumer products, tourism, and insurance Key Points and Arguments 1. **Strategic Focus**: Fosun International is implementing a "slimming down" strategy aimed at systematically enhancing profitability, cash flow generation, and balance sheet health over the next five years, with a gradual increase in shareholder dividends currently maintained at around 20% [2][3][4] 2. **Core Subsidiaries**: The four core subsidiaries of Fosun International are: - **Fosun Health**: Rapid growth in innovative drug revenues with multiple products showing significant potential - **Yuyuan**: Strengthened profitability in fashion jewelry and potential recovery in the liquor business due to consumer recovery - **Fosun Tourism**: Accelerating global resort network expansion with expected profitability improvements - **Fosun Insurance**: Strong premium income growth, leading market share in Portugal [4][6] 3. **Debt Management**: The company aims to reduce interest-bearing debt from a historical peak of 120 billion RMB to below 60 billion RMB, with a target for public market debt to be below 25% [2][8][10] 4. **International Market Performance**: Fosun Pharma has ten products approved in international markets, with strong sales performance and expected significant growth over the next three years, particularly in innovative products like PD-L1 and ADC [5][6] 5. **Yuyuan's Business Transformation**: Yuyuan is actively transforming its brand image and focusing on younger demographics, with new product lines and marketing strategies to align with current consumer trends [2][8] 6. **Capital Allocation**: The company prioritizes capital allocation towards four main industries: health (Fosun Pharma), consumer (Yuyuan and Fosun Tourism), wealth (Portuguese insurance), and manufacturing (Hainan Mining) [4][10] 7. **Operational Efficiency**: The management emphasizes improving operational efficiency and reducing costs, particularly in response to declining profitability in some Yuyuan segments [10][11] 8. **Future Growth Drivers**: Expected growth from innovative drug commercialization, new village expansions, and high-end tourism models is anticipated to contribute to revenue and profit from 2026 to 2027 [11] Other Important Insights - **Market Expansion**: HR Company's gastric cancer surgery phase 3 registration has been successful, with commercialization in over 30 countries, and the U.S. market approval will follow local clinical approval timelines [7] - **IPO Plans**: Fosun Pharma is initiating A-share IPO guidance, which may enhance the valuation of its assets and the overall group [9] - **Collaboration with Clavis Bio**: Fosun Pharma's collaboration involves shared development responsibilities, with specific details to be disclosed publicly [9] This summary encapsulates the essential insights from the conference call, highlighting the strategic direction, financial health, and growth prospects of Fosun International and its subsidiaries.

智通财经APP讯，复星国际(00656)发布公告，于2026年2月4日，本公司的间接全资附属公司浙江复星商 业发展有限公司(复星商发)与浙江商盟科技有限公司(商盟科技)、亚东星辰创业投资有限公司(亚东星辰) 及宁波梅山保税港区统付企业管理合伙企业(有限合伙)(宁波统付)订立一份《增资协议书》。复星商发 同意以现金人民币1.05亿元认购商盟科技新增注册资本，对应取得商盟科技增资后51.0879%的股权。 商盟支付为全球客户提供一站式收付解决方案，跨境支付场景涵盖跨境电商、跨境贸易、跨境商旅等领 域，国内支付场景涵盖文旅、消费金融、新零售等领域，具备稳健的业务基础与良好的发展潜力。 透过本次增资，本公司可分享商盟科技未来成长收益，同时藉助商盟科技与本集团线上线下生态的协同 效应，连结境内及跨境各类业务场景。 截至本公告日，商盟科技持有商盟支付 100%股权。商盟支付核心资质完备，持有中国支付业务许可证 和跨境人民币许可，支付业务许可证的许可事项为储值账户运营 I类、储值账户运营 II类(浙江省、上海 市);同时，商盟科技持有香港金钱服务经营者(Money Service Operator)牌照，与商盟支付的境内支 ...

商盟支付为全球客户提供一站式收付解决方案，跨境支付场景涵盖跨境电商、跨境贸易、跨境商旅等领 域，国内支付场景涵盖文旅、消费金融、新零售等领域，具备稳健的业务基础与良好的发展潜力。 透过本次增资，本公司可分享商盟科技未来成长收益，同时藉助商盟科技与本集团线上线下生态的协同 效应，连结境内及跨境各类业务场景。 截至本公告日，商盟科技持有商盟支付 100%股权。商盟支付核心资质完备，持有中国支付业务许可证 和跨境人民币许可，支付业务许可证的许可事项为储值账户运营 I类、储值账户运营 II类(浙江省、上海 市);同时，商盟科技持有香港金钱服务经营者(Money Service Operator)牌照，与商盟支付的境内支付体 系形成协同，共同构建起金融级境内外一体化支付系统。 智通财经APP讯，复星国际(00656)发布公告，于2026年2月4日，本公司的间接全资附属公司浙江复星商 业发展有限公司(复星商发)与浙江商盟科技有限公司(商盟科技)、亚东星辰创业投资有限公司(亚东星辰) 及宁波梅山保税港区统付企业管理合伙企业(有限合伙)(宁波统付)订立一份《增资协议书》。复星商发 同意以现金人民币1.05亿元认购商盟科技新增 ...